Forget millennials – cash in on golden oldies

IT MAY be too early to invest in the life-extending biotechnology firms being set up by Jeff Bezos and others.

But Laith Khalaf, at Hargreaves Lansdown, suggests more downto-earth investments for anyone wanting to benefit from an ageing population and longer lifespans. He said: ‘AstraZeneca and GlaxoSmithKline are pharmaceutical firms that look set to benefit. And insurers like Legal & General or Aviva, and asset managers such as Standard Life Aberdeen or Schroders, could see exposure to new pensions freedoms.’

He also suggested cruise liner operator Carnival as being a leisure company ‘directed to the silver pound’.

Khalaf added: ‘Of all those, we quite like Legal & General. It has lots in its favour: an ageing demographic and pensions autoenrolment at the other end.’